XML 50 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Supplemental information
 12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Supplemental information Supplemental information
The Company operates as one reporting segment. The following table presents long-lived assets by location:
December 31,
 20242023
United States$55,348 $41,634 
Israel8,569 8,317 
Switzerland21,215 7,733 
Others7,339 5,179 
Total long-lived assets $92,471 $62,863 
Restructuring
In November 2023, the Company announced a series of actions to strengthen and optimize its business operations to support near-term growth drivers and long-term value creation. The plan included a reduction in headcount of approximately 200 employees or 13% of the Company's then current workforce. The Company incurred restructuring costs (including severance pay, garden leave payments, etc.) for the years ended December 31, 2024, 2023 and 2022, as follows:
Year ended December 31,
 202420232022
Cost of revenues$52 $262 $— 
Research, development and clinical studies275 2,070 — 
Sales and marketing1,512 2,404 — 
General and administrative164 1,495 — 
Total restructuring cost
$2,003 $6,231 $— 
Restructuring costs paid during the period
$5,455 $2,753 $— 
These restructuring costs were offset by accrual reversals for the years ended December 31, 2024, 2023 and 2022 in the amount of $369, $3,041 and $0, respectively, which relate to the terminated employees' exits from the Company’s cash incentive plans. These restructuring costs were further offset by forfeited equity-based compensation expense reversals for the years ended December 31, 2024, 2023 and 2022 in the amount of $1,991, $9,313 and $0 , respectively, which relate to the terminated employees' exits from the Company’s equity incentive plan.